Wednesday, August 20, 2025 9:18:32 AM
As commented by others on this board, I also have to believe that murine models of lifespan are in progress, if not already completed.
I'm one of the others. I've long contended that Anavex has privately conducted studies of their Sigma-1 receptor agonist drugs on the lab roundworm, Caenorhabditis elegans. C. elegans is a standard lab animal used to test anti-aging mechanisms of drugs, toxins, and nutrients.
Specifically, blarcamesine’s studies demonstrated effect of enhanced autophagic flux in human cells and in C. elegans as well as increased proteostasis capacity and ability to promote autophagosome biogenesis, autophagic cargo reception, and lysosome fusion.
Doubtless, yes, Anavex has conducted parallel studies in murines, too. They know a lot more about the efficacies, safety, and applications of their drugs than they've publicly revealed. At the right time, it will all become public.
Recent AVXL News
- Anavex shares collapse after CHMP issues negative signal on Alzheimer’s therapy • IH Market News • 11/14/2025 01:45:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:42:01 PM
- Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease • GlobeNewswire Inc. • 11/14/2025 12:30:00 PM
- Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group • GlobeNewswire Inc. • 10/29/2025 11:30:00 AM
- Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ • GlobeNewswire Inc. • 10/10/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2025 12:42:50 AM
- Anavex shares climb on upbeat results from schizophrenia trial • IH Market News • 10/02/2025 12:45:17 PM
- Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program • GlobeNewswire Inc. • 10/02/2025 11:35:00 AM
- Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/02/2025 11:30:00 AM
- Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial • GlobeNewswire Inc. • 09/30/2025 12:30:00 PM
- Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial • GlobeNewswire Inc. • 09/09/2025 11:30:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 • GlobeNewswire Inc. • 09/02/2025 11:30:00 AM
- Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine • GlobeNewswire Inc. • 08/26/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 09:30:21 PM
- Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease • GlobeNewswire Inc. • 08/20/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2025 08:08:20 PM
- Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/12/2025 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 • GlobeNewswire Inc. • 08/05/2025 11:30:00 AM
- Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 07/31/2025 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2025 08:48:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/24/2025 04:15:19 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/14/2025 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 09:25:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/09/2025 09:30:47 PM
ECGI Appoints AI Platform Architect as CTO to Build Mortgage Tokenization Infrastructure • ECGI • Nov 13, 2025 8:30 AM
Alliance Creative Group (ACGX) Releases 2025 Q3 Quarterly Financial and Disclosure Report • ACGX • Nov 13, 2025 4:40 AM
The Hidden Force Behind the AI Revolution • META • Nov 12, 2025 9:00 AM
The Clean Energy Breakthrough That Could Power the AI Era • MAXXF • Nov 12, 2025 9:00 AM
ECGI Highlights Fintech Expansion Through RezyFi Acquisition and Tokenized Mortgage Platform in Shareholder Letter • ECGI • Nov 11, 2025 8:30 AM
The New Gold Rush of the AI Era • ESAU • Nov 10, 2025 9:00 AM
